BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating ...

A patient in his mid-40s is brought to the hospital for a first-time seizure. Medics report that his wife heard him groan and then witnessed about 30 seconds of generalized tonic-clonic seizure ...

Patients with multiple sclerosis (MS) have almost double the risk for seizures, with the risk even greater with sphingosine-1-phosphate receptor (S1PR) modulators, results of a new meta-analysis of ...

The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...

A new 16-week study of 204 adult epilepsy patients found that 98% of participants believe that all patients with epilepsy should have a seizure action plan (SAP), regardless of seizure status. These ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Please provide your email address to receive an email when new articles are posted on . Patients who had a seizure prior to shoulder stabilization had a 29% recurrent instability rate. This was ...

NeuroOne's OneRF® Ablation System has successfully kept a patient seizure-free for over a year, enhancing her quality of life. NeuroOne Medical Technologies Corporation has announced that Clara, an ...

Pediatric patients with autism spectrum disorder (ASD) hospitalized with acute sinusitis have increased rates of seizures, ...

Perampanel was found effective and safe for prolonged use in children with epilepsy, according to one study. After its 2012 approval as an antiseizure medication, perampanel (Fycompa) has been found ...

(WHTM)– The UPMC Neurological Institute is expanding specialized care for Midstate residents with epilepsy or seizure disorders. UPMC announced Tuesday that it has added three fellowship-trained ...